Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2002-08-12
2010-12-14
Azpuru, Carlos A (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
Reexamination Certificate
active
07850984
ABSTRACT:
Described are methods for protecting the female reproductive system against natural and artificial insults by administering to women a composition comprising an agent that antagonizes one or more acid sphingomyelinase (ASMase) gene products. Specifically, methods disclosed herein serve to protect women's germline from damage resulting from cancer therapy regimens including chemotherapy or radiotherapy. In one aspect, the method preserves, enhances, or revives ovarian function in women, by administering to women a composition containing sphingosine-1-phosphate, or an analog thereof. Also disclosed are methods to prevent or ameliorate menopausal syndromes and to improve in vitro fertilization techniques.
REFERENCES:
patent: 5712262 (1998-01-01), Spiegel
patent: 5773278 (1998-06-01), Schuchman et al.
patent: 5877167 (1999-03-01), Igarashi et al.
patent: 2007/0157331 (2007-07-01), Tilly et al.
Moirta et al, oocye Apoptosis is Supressed by Disrutpion of the Acid Sphingomyelinase gene or by Sphingosine—1-phosphate therapy, Nature Medicine, (Oct. 2000) vol. 6, No. 10, pp. 1109-1114.
Gong et al., “The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage”,Nature, (1999) 399:806-809.
Springer et al., “Involvement of Apoptosis in 4-Vinylcyclohexene Diepoxide-Induced Ovotoxicity in Rats”,Toxicol. Appl. Pharmacol., (1996) 139:394-401.
Perez and Tilly, “Cumulus cells are required for the increased apooptotic potential in oocytes of aged mice”,Human Reproduction(1997) 12:2781-2783.
Perez et al., “Prolongation of ovarian lifespan into advanced chronological age byBax-deficiency”,Nature Genetics, (1999) 21:200-203.
Kugu et al., “Analysis of apoptosis and expression ofbcl-2 gene family members in th ehuman and baboon ovary”,Cell Death and Differentiation, (1998) 5:67-76.
Flaws et al., “Vasoactive intestinal peptide-mediated suppression of apoptosis in the Ovary: Potential Mechanisms of Action and Evidence of a conserved antiatreogenic role through evolution”,Endocrinol. (1995) 136:4351-4359.
Tilly et al., “Epidermal growth factor and basic fibroblast growth factor suppress the spontaneous onset of apoptosis in cultured rat ovarian granulosa cells and follicles by a tyrosine kinase-dependent mechanism”,Mol. Endocrinol., (1992) 6:1942-1950.
Johnson et al., “Susceptibility of Avian Ovarian Granulosa cells to apoptosis is dependent upon stage of follicle development and is related to endogenous lvels ofbcl-xlong gene expression”,Endocrinol. (1996) 137:2059-2066.
Greco RM. et al., “Differences in cell division and thymidine incorporation with rat and primate fibroblasts in collagen lattices”,Tissue Cell., (1992) 24:6 843-851.
Bergeron, L., et al., “Defects in Regulation of Apoptosis in Caspase-2-Deficient Mice”, Genes. Dev., vol. 12, pp. 1304-1314 (1998).
Goetzl, E., et al., “Diversity of Cellular Receptors and Functions for the Lysophospholipid Growth Factors Lysophosphatidic Acid and Sphingosine 1-Phosphate”, FASEB J., vol. 12, No. 15, pp. 1589-1598 (1998).
Perez, G., et al., “Apoptosis-Associated Signaling Pathways Are Required for Chemotherapy-Mediated Female Germ Cell Destruction”, Nat. Med., vol. 3, No. 11, pp. 1228-1232 (1997).
Cuvillier, O., et al., “Suppression of Ceramide-Mediated Programmed Cell Death by Sphingosine-1-Phosphate”, Nature, vol. 381, No. 6585, pp. 800-803 (1996).
K., Horinouchi, et al., “Acid Sphingomyelinase Decicient Mice: A Model of Types A and B Niemann-Pick Disease”, Nat. Genet., vol. 10, No. 3, pp. 288-293 (1995).
Edsall, L. C., et al., “Involvement of Sphingosine 1-Phosphate in Nerve Growth Factor-Mediated Neuronal Survival and Differentiation”, J. Neurosci., vol. 17, pp. 6952-6960 (1977).
Abstract, Tilly et al., “Sphingolipid signaling in gonadal development and function” abstract No. 623565, Chem. Abstracts vol. 131, No. 349341 (1999).
Abstract, Morita et al., “Oocyte apoptosies is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy”, abstract No. 736446, Chem. Abstracts, vol. 134, No. 25322 (2000).
Abstract, Casper et al., “Protecting the Female Germ Line from Cancer Therapy”, Elsevier Science Publishers, Amsterdam. No. 2000375706 (2000).
Morita, Y., et al., “Oocyte Apoptosis: Like Sand Through an Hourglass”, Dev. Biol., vol. 213, No. 1, pp. 1-17 (1999).
Morita, Y., et a1., “Requirement for Phosphatidylinositol-3″-Kinase in Cytokine-Mediated Germ Cell Survival During Fetal Oogenesis in the Mouse”, Endocrinology, vol. 140, No. 2, pp. 941-949 (1999).
Morita, Y., et al., “Targeted Expression of Bcl-2 in Mouse Oocytes Inhibits Ovarian Follicle Atresia and Prevents Spontaneous and Chemotherapy-Induced Oocyte Apoptosis In Vitro”, Mol. Endocrinology, vol. 13, No. 6, pp. 841-850 (1999).
Hla, T., et al., “Sphingosine-1-Phosphate: Extracellular Mediator or Intracellular Second Messenger?”, Biochem. Pharmacol, vol. 58, No. 2, pp. 201-207 (1999).
Perez, G., et al., “Fragmentation and Death (A.K.A. Apoptosis) of Ovulated Oocytes”, Mol. Human Reprod., vol. 5, No. 5, pp. 414-420 (1999).
Reynolds, T.., “Cell Death Genes May Hold Clues to Preserving Fertility After Chemotherapy”, J. Nat'l Cancer Inst., vol. 91, No. 8, pp. 664-666 (1999).
Perez, G., et al., “Prolongation of Ovarian Lifespan Into Advanced Chronological Age by Bax-Deficiency”, Nature Genet., vol. 21, No. 2, pp. 200-203 (1999).
Spiegel, S., Sphingosine 1-Phosphate: A Prototype of a New Class of Second Messengers, J. Leukocyte Biol., vol. 65, No. 3, pp. 341-344 (1999).
Spiegel, S., et al., “Sphingosine-1-Phosphate in Cell Growth and Cell Death”, Ann. N.Y. Acad. Sci., vol. 845, pp. 11-18 (1998).
Gougeon, Endocr Rev. 17, 121 (1996).
Morita, Y. et al., Nat. Med. 6, 1109-1114 (2000).
Waxman, Soc. Med. 76,144 (1983).
Familiari et al., Hum. Reprod. 8, 2080 (1993).
Ried & Jaffee, Semin. Roentgenol. 29, 6 (1994).
Reichman & Green, Monogr. Natl. Cancer Inst. 16, 125 (1994).
Tilly & Ratts, Contemp. Obstet. Gynecol. 41, 59 (1996).
Tilly, Rev. Reprod. 1, 162 (1996).
Tilly et al., Cell Death Differ. 4, 180 (1997).
Tilly et al., Endocrinology 136, 1394 (1995).
Tilly et al., Endocrinology 136-232 (1995).
Adams & Cory, Science 281, 1322 (1998).
Green, Cell 94,695 (1998).
Thornberry & Lazebnik, Science 281, 1312 (1998).
Reed, Oncogene 17, 3225 (1998).
Korsmeyer, Cancer Res. 59,1693 (1999).
Keren-Tal et al., Exp. Cell Res. 218, 283 (1995).
Makrigiannakis et al., J. Clin. Endocrinol. Metab. 85, 449 (2000).
Ratts et al., Endocrinology 136, 3665 (1995).
Knudson et al., Science 270,99 (1995).
Flaws et al., Endocrinology 136, 5042 (1995).
Maravei et al., Cell Death Differ. 4, 707 (1997).
Boone & Tsang, Biol. Reprod. 58, 1533 (1998).
Hannun, Science 274, 1855 (1996).
Kolesnick & Kronke, Annu. Rev. Physiol. 60:643 (1998).
Witty et al., Endocrinology 137, 5269 (1996).
Kaipia et al., Endocrinology 137, 4864 (1996).
Martimbeau & Tilly, Clin. Endocrinol. 46, 241 (1997).
Spiegal et al., Curr. Opin. Cell Biol. 8, 159 (1996).
Hofmann & Dixit, Trends Biochem. Sci 23, 374 (1998).
Watts et al., Cell Death Differ. 6, 105 (1999).
Ko & Prives, Genes Dev. 10, 1054 (1996).
Ding et al., Crit. Rev. Oncog. 9, 83 (1998).
Declaration of Dr. Jonathan L. Tilly Under 37 C.F.R. §1.132 dated Feb. 7, 2008.
Schissel, S. et al, “Secretory Sphingomyellnase, a Product of the Acid Sphingomyelinase Gene, Can Hydrolyze Atherogenic Lipoproteins at Neutral pH”, The Journal of Biological chemistry, vol. 273, No. 5, pp. 2738-2746Issue of Jan. 30, 1998.
Levran O. et al., “Niemann-Pick disease: A Frequent Missense Mutation in the Acid Sphingomyelinase Gene of Ashkenazl Jewish Type A and B Patients”, Proc. Natl. Acad. Sci. USA vol. 88, pp. 3748-3752,
Kolesnick Richard N.
Tilly Jonathan L.
Azpuru Carlos A
Edwards Angell Palmer & & Dodge LLP
Hunter-Ensor, Esq. Melissa
Lauro, Esq. Peter C.
Memorial Sloan-Kettering Cancer Center
LandOfFree
Protection of the female reproductive system from natural... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protection of the female reproductive system from natural..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protection of the female reproductive system from natural... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4226201